Ingalls & Snyder LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 24.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 622,901 shares of the biopharmaceutical company’s stock after selling 205,415 shares during the quarter. Pfizer makes up about 1.2% of Ingalls & Snyder LLC’s holdings, making the stock its 19th biggest position. Ingalls & Snyder LLC’s holdings in Pfizer were worth $22,238,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Janus Henderson Group PLC raised its position in Pfizer by 243.5% in the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after acquiring an additional 9,339,749 shares during the period. Vanguard Group Inc. raised its position in Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares during the period. Renaissance Technologies LLC bought a new stake in Pfizer in the second quarter worth about $268,389,000. Canada Pension Plan Investment Board raised its position in Pfizer by 249.6% in the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after acquiring an additional 7,649,416 shares during the period. Finally, Parametric Portfolio Associates LLC raised its position in Pfizer by 42.1% in the second quarter. Parametric Portfolio Associates LLC now owns 17,818,368 shares of the biopharmaceutical company’s stock worth $598,519,000 after acquiring an additional 5,281,314 shares during the period. Institutional investors and hedge funds own 69.75% of the company’s stock.

Shares of Pfizer Inc. (PFE) opened at $36.94 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market cap of $221,708.50, a P/E ratio of 14.88, a P/E/G ratio of 2.63 and a beta of 1.01. Pfizer Inc. has a twelve month low of $30.90 and a twelve month high of $37.35.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. Pfizer’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.61 EPS. analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

Pfizer declared that its board has approved a share buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.68%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is 79.01%.

In related news, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders have sold a total of 36,800 shares of company stock worth $1,327,248 in the last ninety days. 0.06% of the stock is currently owned by insiders.

Several analysts have commented on the stock. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Friday, December 15th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Barclays set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, October 16th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company’s stock. Pfizer currently has an average rating of “Buy” and an average price target of $38.77.

TRADEMARK VIOLATION WARNING: “Ingalls & Snyder LLC Has $22.24 Million Position in Pfizer Inc. (PFE)” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/ingalls-snyder-llc-has-22-24-million-position-in-pfizer-inc-pfe/1774077.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.